Context:Local drug delivery agents. Aims: To clinically evaluate the efficacy of Chlorhexidine chip (PerioCol™ CG) with Tetracycline fibers (Periodontal Plus AB™). Settings and Design: Randomized controlled, split mouth study design with an observation period of six months. Materials and Methods: Patients were allocated in 3 experimental treatment groups, Group A: SRP + CHX Chip, Group B: SRP + Tetracycline fibers, and Group C: SRP alone (control group). 420 bleeding sites in 35 patients (18 females and 17 males) with chronic periodontitis (5-8mm probing depth), were evaluated clinically for pocket probing depth (PD), Clinical Attachment level (CAL), and Bleeding on Probing (BoP). Statistical Analysis: T-test and CV. Results: All the treatment groups were found to be efficacious as demonstrated by improvement in PD, CAL, and BoP. In the short term, CHX group showed increased gain of CAL but on long term observation the Tetracycline fiber group showed better consistent clinical results in comparison to the other two groups. Conclusions: Group B (SRP + Tetracycline fibers) resulted in better optimum clinical results in comparison to the other two treatment groups.
Peripheral ossifying fibroma (POF) is a common solitary gingival growth thought to arise from the periodontal ligament. Though the etiology of POF remains unknown, some investigators consider it an inflammatory or reactive process, while others suggest it is a neoplastic process. Here, we present a case of POF in a 10-year-old boy, affecting the maxillary anterior gingiva along with its clinical, radiographic, histologic characteristics, differential diagnosis, treatment and one year follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.